About the ViraxShield Team

Greg Pilant

Founder and Chairman of DGH  

Mr. Pilant is a lifelong entrepreneur and founder of Greystone Pharmaceuticals, Inc.  Prior to Greystone he was CEO of Medical and Pharma Companies since 1985 including Stanley Pharmaceuticals, National Labs, and MedStat.  Mr. Pilant has set-up manufacturing facilities in China, Europe, the Middle East and the US and has had 30 years of experience in every aspect of wound care from FDA and CE compliance, reimbursement, manufacturing and distribution.  Mr. Pilant was one of the first fifteen Voted into University of Memphis “Business Hall of Fame.”

 

John R. Brown

Chief Technical Officer

John has over 21 years of experience and expertise in contract manufacturing. His accomplishments span all facets of development, compliance and distribution of FDA regulated products. He has experience in process optimization in building quality design and production. John is a cross functional team builder and works to utilize trans-formative ideas to build a sustainable culture of meeting and exceeding company goals.

 

Norman Blake

Chief Marketing Officer

Norman is the Managing Director for Cosmetech, LLC a contract manufacturer for anti-aging skin products. He serves on the board of High Emotional Lab an audio engineering company that serves senior communities to treat dementia, anxiety and wellness through high quality sound systems delivering their favorite music. Mr. Blake was a Managing Director with Merrill Lynch for 24 years.  He has helped launch and market medical software, telemedicine and wound care companies. He has worked with Mr. Pilant and each member of the team.

 

Dr. Lee Ori

Chief Medical Officer

Dr. Ori graduated from Auburn University Harrison School of Pharmacy (AUHSOP) magna cum laude with his doctorate in pharmacy. He worked for Eli Lilly and Company as a clinical liaison to physicians. Lee presently holds pharmacist license(s) in 10 states and has held numerous executive positions based on his extensive compounding background. These include serving as Director or Pharmaceutical Operations for Optimal Health Labs, LLC, and Chief Medical Officer for Ready Scrip, LLC.

 

Charles Smith

CFO, CPA

Mr. Smith graduated from Boston University School of Management and is an experienced CFO with a proven record of establishing cross functional partnerships with management and regulatory, marketing, sales development.  His strengths include financial analysis, budgeting, forecasting and public company filings.  He has been the CFO with Vivi Holdings, Inc a mobile payments company since 2016.

 

David Dunlap

Corporate Council

David is an experienced corporate attorney who has been in practice for 22 years and served as general council and secretary of a company that develops senior living communities. He founded and operates his own firm in 2010, where he continues to practice focusing on commercial transactions, contracts and business law. He is a graduate of Wake Forest and University of Tennessee Law.

 

Why We Developed the VIRAXSHIELD™ VIRAL DEFENSE SYSTEM


We developed our Viral Defense System because of the spread of the Coronavirus and the need coming from the CDC.

According to the Center for Disease Control (CDC), the new coronavirus named “SARS-CoV-2” and the disease it causes is named “coronavirus disease 2019,(COVID-19) spreads easily with a death rate that is higher than any other virus in history. On January 30, 2020, the World Health Organization (WHO) declared the outbreak a “public health emergency of international concern,” and the coronavirus has since spread exponentially throughout the world. This is particularly due to the contact-spread component of the disease. 

COVID-19 can survive on surfaces for days. One of the major ways the virus spreads is through hand-to-hand contact and through contact by touching a surface where the virus has landed and then touching one's mouth, nose or eyes. The CDC recommends regular and thorough hand washing to help prevent the spread of the disease, but hand washing only kills the virus already on one's hands. The likelihood of viral contact through is expanding daily. 

DGH sister company, DGH Pharma, developed two essential products: ViraXshield™  Antibacterial Soap and ViraXshield™  Your Invisible Glove™.  Individuals must wash their hands properly and regularly.  ViraXshield™  Antibacterial Soap ensures the best and most thorough clean possible by killing the virus with a professional-grade cleanser. 

The problem has become that people believe if they wash their hands or sanitize them with an alcohol-based sanitizer, they are germ free and will stay that way. From the second they are through washing or sanitizing they are immediately susceptible again. People unknowingly touch a contaminated surface or touch someone and become contaminated.  A continuing virus-killing screen of protection is the only solution to the problem.  ViraXshield™  Your Invisible Glove™ provides a minimum of four hours of virus-killing protection and uses a unique, proprietary, and patented mode of action that penetrates the epidermis, the first layer of the skin, to provide continuous virus-killing protection. A normal glove can pick up and spread the virus, but ViraXshield™  Your Invisible Glove™ kills the virus and continues to kill the virus for over four hours. Simply applying ViraXshield™ Your Invisible Glove™ after hand washing with ViraXshield™  Antibacterial Soap provides users the benefit of the newest technology available to maintain the best available protection.

 

The Problem

COVID-19 spreads mostly through tiny droplets of viral particles. These attach to surfaces, which people then touch with their hands, spreading the virus, which enters the body through the eyes, mouth, or nose.  Preliminary research also suggests that those germs may survive for days when they attach themselves to countertops, handrails, and other hard surfaces. The virus can sometimes survive on indoor surfaces for more than 7 to 9 days. In general, COVID-19 will survive for longer time periods on non-porous (water resistant) surfaces, such as stainless steel and plastics, than porous surfaces, such as fabrics and tissues (National Health Service › UK Feb 18, 2020).

Viruses cannot multiply on their own — they must infect the cells of a living creature. Because they aren't actually living entities, using terms like "live" or "survive" to describe viruses outside the body can cause confusion, according to Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Disease.  Viruses outside the body can be better described as either infectious or identifiable — meaning the genetic material that was once inside the virus can be detected via a lab technique like polymerase chain reaction, or PCR. This is usually what advertisements for cleaning products are referring to when they say flu viruses can survive on surfaces for days on end.

Viruses are actually nonliving pieces of genetic code — DNA or RNA — covered in protein coats known as capsids. Flu viruses, such as COVID-19, and many cold viruses also have a viral envelope, meaning the capsid is covered by two layers of lipids similar to the cell membranes found on organisms.  An intact virus is necessary for an infection, but this propensity reduces over time as its capsid and viral envelope begin to degrade. Once weakened, the virus is less able to attach to cells and spread its genetic material. The key is the degradation of the protective layer surrounding the virus.